Clinical Trial Update: Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders [Phase 2]

View source ↗

Summary

A Phase 2 study of HQK-1004 in combination with valganciclovir for Epstein-Barr virus–associated lymphoid malignancies and lymphoproliferative disorders has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies
• Lymphoproliferative Disorders

Drugs mentioned

• HQK-1004
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: HemaQuest Pharmaceuticals Inc. | Conditions: Lymphoid Malignancies, Lymphoproliferative Disorders | Phase 2 | Status: TERMINATED